Anastrozole and celecoxib for endometriosis treatment, good to keep them apart

Reproduction

Volumn 145, Issue 2, 2013, Pages 119-126

  Olivares, Carla N ^a   Bilotas, Mariela A ^a   Ricci, Analia G ^a   Baranao, Rosa Ines ^a   Meresman, Gabriela F ^a  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CD34 ANTIGEN; CELECOXIB; CYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SIZE; CONTROLLED STUDY; ENDOMETRIOSIS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NICK END LABELING; NIDATION; NONHUMAN; PRIORITY JOURNAL; VASCULARIZATION;

ANIMALS; AROMATASE INHIBITORS; CYCLOOXYGENASE 2 INHIBITORS; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; DRUG INCOMPATIBILITY; ENDOMETRIOSIS; FEMALE; MESENTERY; MICE; MICE, INBRED BALB C; NITRILES; PERITONEAL DISEASES; PYRAZOLES; SULFONAMIDES; TRIAZOLES; UTERINE DISEASES;

EID: 84874062230     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-12-0386     Document Type: Article

References (52)

1. Banerjee S, A'Hern R, Detre S, Littlewood-Evans AJ, Evans DB, Dowsett M & Martin LA 2010 Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clinical Cancer Research 16 4178-4187. (doi:10.1158/1078-0432.CCR-10-0456)
2. Banu SK, Lee J, Speights VO Jr, Starzinski-Powitz A & Arosh JA 2008 Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology 149 1180-1189. (doi:10.1210/en.2007-1168)
3. Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E & Bundred NJ 2007 Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. British Journal of Cancer 96 575-582. (doi:10.1038/sj.bjc. 6603593)
4. Basu GD, Pathangey LB, Tinder TL, Gendler SJ & Mukherjee P 2005 Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Research 7 R422-R435. (doi:10.1186/bcr1019)
5. Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J & D'Amato RJ 2006 Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertility and Sterility 85 71-77. (doi:10.1016/j.fertnstert.2005.07.1290)
6. Bilotas M, Meresman G, Stella I, Sueldo C & Baranao RI 2010 Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis. Fertility and Sterility 93 2513-2518. (doi:10.1016/j.fertnstert.2009.08.058)
7. Bocca C, Bozzo F, Bassignana A & Miglietta A 2011 Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Molecular and Cellular Biochemistry 350 59-70. (doi:10.1007/s11010-010-0682-4)
8. Brodie A, Jelovac D & Long BJ 2003 Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clinical Cancer Research 9 455S-459S.
9. Brueggemeier RW, Su B, Sugimoto Y, Diaz-Cruz ES & Davis DD 2007 Aromatase COX in breast cancer: enzyme inhibitors and beyond. Journal of Steroid Biochemistry and Molecular Biology 106 16-23. (doi:10.1016/j.jsbmb.2007.05.021)
10. Bulun SE, Noble LS, Takayama K, MichaelMD, Agarwal V, Fisher C, Zhao Y, Hinshelwood MM, Ito Y & Simpson ER 1997 Endocrine disorders associated with inappropriately high aromatase expression. Journal of Steroid Biochemistry and Molecular Biology 61 133-139. (doi:10.1016/ S0960-0760(97)80004-0)
11. Bulun SE, Yang S, Fang Z, Gurates B, TamuraM& Sebastian S 2002 Estrogen production and metabolism in endometriosis. Annals of the New York Academy of Sciences 955 75-85. (doi:10.1111/j.1749-6632.2002. tb02767.x)
12. Bundred NJ & Barnes NL 2005 Potential use of COX-2-aromatase inhibitor combinations in breast cancer. British Journal of Cancer 93 (Suppl 1) S10-S15. (doi:10.1038/sj.bjc.6602690)
13. Chow LW, Yip AY, LooWT, Lam CK & ToiM2008 Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology 111 13-17. (doi:10.1016/ j.jsbmb.2008.04.004)
14. Cobellis L, Razzi S, De Simone S, Sartini A, Fava A, Danero S, Gioffre W, Mazzini M & Petraglia F 2004 The treatment with a COX-2 specific inhibitor is effective in the management of pain related to endometriosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology 116 100-102. (doi:10.1016/j.ejogrb.2004.02.007)
15. Dandekar DS, Lopez M, Carey RI & Lokeshwar BL 2005 Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and-9 in prostate cancer cells. International Journal of Cancer 115 484-492. (doi:10.1002/ijc. 20878)
16. Davies G, Martin LA, Sacks N & Dowsett M 2002 Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Annals of Oncology 13 669-678. (doi:10.1093/annonc/mdf125)
17. Dirix LY, Ignacio J, Nag S, Bapsy P, Gomez H, Raghunadharao D, Paridaens R, Jones S, Falcon S, Carpentieri M et al. 2008 Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. Journal of Clinical Oncology 26 1253-1259. (doi:10.1200/JCO.2007.13.3744)
18. Dogan E, Saygili U, Posaci C, Tuna B, Caliskan S, Altunyurt S & Saatli B 2004 Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib. Fertility and Sterility 82 (Suppl 3) 1115-1120. (doi:10.1016/j.fertnstert.2004.06.033)
19. Ebert AD, Bartley J & David M 2005 Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions-old answers? European Journal of Obstetrics, Gynecology, and Reproductive Biology 122 144-150. (doi:10.1016/j.ejogrb.2005.04.017)
20. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D, Folkman J, D'Amato RJ & Rupnick MA 2005 Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertility and Sterility 83 171-181. (doi:10.1016/j.fertnstert.2004. 06.058)
21. Fagotti A, Ferrandina G, Fanfani F, Legge F, Lauriola L, Gessi M, Castelli P, Barbieri F, Minelli L & Scambia G 2004 Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters. Human Reproduction 19 393-397. (doi:10.1093/humrep/deh054)
22. Falandry C, Canney PA, Freyer G & Dirix LY 2009 Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Annals of Oncology 20 615-620. (doi:10.1093/ annonc/mdn693)
23. Fang Z, Yang S, Gurates B, Tamura M, Simpson E, Evans D & Bulun SE 2002 Genetic or enzymatic disruption of aromatase inhibits the growth of ectopic uterine tissue. Journal of Clinical Endocrinology and Metabolism 87 3460-3466. (doi:10.1210/jc.87.7.3460)
24. Geisler J 2011 Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole-of clinical importance? British Journal of Cancer 104 1059-1066. (doi:10.1038/bjc.2011.58)
25. Ghosh N, Chaki R, Mandal V & Mandal SC 2010 COX-2 as a target for cancer chemotherapy. Pharmacological Reports 62 233-244.
26. Goss PE & Strasser-Weippl K 2004 Prevention strategies with aromatase inhibitors. Clinical Cancer Research 10 372S-379S. (doi:10.1158/1078-0432.CCR- 031210)
27. Grummer R 2006 Animal models in endometriosis research. Human Reproduction Update 12 641-649. (doi:10.1093/humupd/dml026)
28. Gupta S, Adhami VM, SubbarayanM,MacLennan GT, Lewin JS, Hafeli UO, Fu P & Mukhtar H 2004 Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Research 64 3334-3343. (doi:10.1158/0008-5472.CAN-03-2422)
29. Hayes EC & Rock JA 2002 COX-2 inhibitors and their role in gynecology. Obstetrical & Gynecological Survey 57 768-780. (doi:10.1097/ 00006254-200211000-00023)
30. Hull ML, Prentice A, Wang DY, Butt RP, Phillips SC, Smith SK & Charnock-Jones DS 2005 Nimesulide, a COX-2 inhibitor, does not reduce lesion size or number in a nude mouse model of endometriosis. Human Reproduction 20 350-358. (doi:10.1093/humrep/deh611)
31. Kyama CM, Overbergh L, Mihalyi A, Meuleman C, Mwenda JM, Mathieu C & D'Hooghe TM 2008 Endometrial and peritoneal expression of aromatase, cytokines, and adhesion factors in women with endometriosis. Fertility and Sterility 89 301-310. (doi:10.1016/j.fertnstert.2007. 02.057)
32. Laschke MW, Elitzsch A, Scheuer C, Vollmar B & Menger MD 2007 Selective cyclo-oxygenase-2 inhibition induces regression of autologous endometrial grafts by down-regulation of vascular endothelial growth factor-mediated angiogenesis and stimulation of caspase-3-dependent apoptosis. Fertility and Sterility 87 163-171. (doi:10.1016/j.fertnstert. 2006.05.068)
33. Lousse JC, Van Langendonckt A, Defrere S, Ramos RG, Colette S & Donnez J 2012 Peritoneal endometriosis is an inflammatory disease. Frontiers in Bioscience 4 23-40. (doi:10.2741/358)
34. Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B et al. 2011 Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clinical Breast Cancer 11 221-227. (doi:10.1016/j.clbc. 2011.03.022)
35. Machado DE, Berardo PT, Landgraf RG, Fernandes PD, Palmero C, Alves LM, Abrao MS & Nasciutti LE 2010 A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model. Fertility and Sterility 93 2674-2679. (doi:10.1016/ j.fertnstert.2009.11. 037)
36. Matsuzaki S, Canis M, Pouly JL, Wattiez A, Okamura K & Mage G 2004 Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium. Fertility and Sterility 82 1309-1315. (doi:10. 1016/j.fertnstert. 2004.03.059)
37. Mendes RA, Carvalho JF & Waal I 2009 An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncology 45 e124-e128. (doi:10.1016/j.oraloncology.2009.03.016)
38. Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, TesoneM& Rumi LS 2000 Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertility and Sterility 74 760-766. (doi:10.1016/S0015- 0282(00)01522-3)
39. Meresman GF, Bilotas M, Abello V, Buquet R, Tesone M & Sueldo C 2005 Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis. Fertility and Sterility 84 459-463. (doi:10.1016/j.fertnstert.2005.01.137)
40. Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R & Rodemann HP 2007 Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro. Radiotherapy and Oncology 82 229-238. (doi:10.1016/j.radonc.2006.11.018)
41. Olivares C, Bilotas M, Buquet R, Borghi M, Sueldo C, Tesone M & Meresman G 2008 Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Human Reproduction 23 2701-2708. (doi:10.1093/humrep/den315)
42. Olivares C, Ricci A, Bilotas M, Baranao RI & Meresman G 2011 The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertility and Sterility 96 428-433. (doi:10.1016/ j.fertnstert.2011.05.063)
43. Ota H, Igarashi S, Sasaki M & Tanaka T 2001 Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Human Reproduction 16 561-566. (doi:10.1093/ humrep/16.3.561)
44. Ozawa Y, Murakami T, Tamura M, Terada Y, Yaegashi N & Okamura K 2006 A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice. Fertility and Sterility 86 (Suppl 4) 1146-1151. (doi:10.1016/j.fertnstert.2006. 01.057)
45. Ozkan S, Murk W & Arici A 2008 Endometriosis and infertility: epidemiology and evidence-based treatments. Annals of the New York Academy of Sciences 1127 92-100. (doi:10.1196/annals.1434.007)
46. Pelch KE, Schroder AL, Kimball PA, Sharpe-Timms KL, Davis JW & Nagel SC 2010 Aberrant gene expression profile in a mouse model of endometriosis mirrors that observed in women. Fertility and Sterility 93 1615-1627. (doi:10.1016/j.fertnstert.2009.03.086)
47. Ricci AG, Olivares CN, Bilotas MA, Meresman GF & Baranao RI 2011 Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reproductive Sciences 18 614-622. (doi:10.1177/1933719110395406)
48. Rocha AL, Reis FM & Petraglia F 2012 New trends for the medical treatment of endometriosis. Expert Opinion on Investigational Drugs 21 905-919. (doi:10.1517/13543784.2012.683783)
49. Sirianni R, Chimento A, De Luca A, Zolea F, Carpino A, Rago V, Maggiolini M, Ando S & Pezzi V 2009 Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. Journal of Biological Chemistry 284 28905-28916. (doi:10.1074/jbc.M109.041020)
50. Wadman M 2007 The pain game. Nature 448 400-401. (doi:10.1038/ 448400a)
51. Wang XQ, Yu J, Luo XZ, Shi YL, Wang Y, Wang L & Li DJ 2010 The high level of RANTES in the ectopic milieu recruits macrophages and induces their tolerance in progression of endometriosis. Journal of Molecular Endocrinology 45 291-299. (doi:10.1677/JME-09-0177)
52. Wu MH, Lu CW, Chuang PC & Tsai SJ 2010 Prostaglandin E2: the master of endometriosis? Experimental Biology and Medicine 235 668-677. (doi:10.1258/ebm.2010.009321)